Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await
Cabaletta Bio shares gained in light premarket action Monday, bouncing after drifting out of focus for some traders. The autoimmune cell-therapy firm is set to appear at a healthcare conference in two days, with key clinical data due out in London later this week. Shares ended Friday at $3.78. Pre-market quotes showed the stock at $3.92, a 3.7% gain. Only a few thousand shares traded before the bell, so the premarket jump could fade when the Nasdaq opens.